IRBIT a Master Regulator of Cell Physiology

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

unexpected functions of slug (snai2), a master regulator of emt, in metastatic prostate cancer cell lines

slug (snai2), a regulator of epithelial-to-mesenchymal transition (emt), is a zinc finger transcription factor involved in neurulation. intriguingly, snai2 gene expression has been linked to the aggressiveness of neuroblastoma, melanoma and lung, colon, ovarian and breast carcinoma. of note, many metastatic cancers recapitulate emt to enhance cell motility and invasion. moreover, metastasis is ...

متن کامل

NKG2D: A Master Regulator of Immune Cell Responsiveness

NKG2D is an activating receptor that is mostly expressed on cells of the cytotoxic arm of the immune system. Ligands of NKG2D are normally of low abundance, but can be induced in virtually any cell in response to stressors, such as infection and oncogenic transformation. Engagement of NKG2D stimulates the production of cytokines and cytotoxic molecules and traditionally this receptor is, theref...

متن کامل

What is a Master Regulator?

Copyright: © 2013 Chan SSK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The term “master regulator” or “master regulatory gene” was first coined by Susumu Ohno over 30 years ago for a “gene that occ...

متن کامل

Interleukin-12: A master regulator

Early resistance to pathogens requires a swift response from NK cells. In 1989, Giorgio Trinchieri identified an NK growth factor and activator, later called interleukin-12 (IL-12). This discovery helped reveal the regulatory link between innate and adaptive immunity.

متن کامل

EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Epstein-Barr virus (EBV) was first discovered in cells from a patient with Burkitt lymphoma (BL), and is now known to be a contributory factor in 1-2% of all cancers, for which there are as yet, no EBV-targeted therapies available. Like other herpesviruses, EBV adopts a persistent latent infection in vivo and only rarely reactivates into replicative lytic cycle. Although latency is associated w...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: MOJ Cell Science & Report

سال: 2017

ISSN: 2374-6912

DOI: 10.15406/mojcsr.2017.04.00078